53 results on '"Satolli MA"'
Search Results
2. Sentinel lymph node mapping in colorectal cancer: a feasibility study
- Author
-
Evangelista, W., Satolli, Ma, Malossi, A., Mussa, Baudolino, and Sandrucci, Sergio
- Published
- 2002
3. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma
- Author
-
Satolli Maria A, Stacchini Alessandra, Castellano Giancarlo, Chiappino Isabella, Baiocco Cinzia, Bello Marilena, Galetto Alessandra, Matera Lina, Mele Michele, Sandrucci Sergio, Mussa Antonio, Bisi Gianni, and Whiteside Theresa L
- Subjects
Medicine - Abstract
Abstract Background Besides being the effectors of native anti-tumor cytotoxicity, NK cells participate in T-lymphocyte responses by promoting the maturation of dendritic cells (DC). Adherent NK (A-NK) cells constitute a subset of IL-2-stimulated NK cells which show increased expression of integrins and the ability to adhere to solid surface and to migrate, infiltrate, and destroy cancer. A critical issue in therapy of metastatic disease is the optimization of NK cell migration to tumor tissues and their persistence therein. This study compares localization to liver metastases of autologous A-NK cells administered via the systemic (intravenous, i.v.) versus locoregional (intraarterial, i.a.) routes. Patients and methods A-NK cells expanded ex-vivo with IL-2 and labeled with 111In-oxine were injected i.a. in the liver of three colon carcinoma patients. After 30 days, each patient had a new preparation of 111In-A-NK cells injected i.v. Migration of these cells to various organs was evaluated by SPET and their differential localization to normal and neoplastic liver was demonstrated after i.v. injection of 99mTc-phytate. Results A-NK cells expressed a donor-dependent CD56+CD16+CD3- (NK) or CD56+CD16+CD3+ (NKT) phenotype. When injected i.v., these cells localized to the lung before being visible in the spleen and liver. By contrast, localization of i.a. injected A-NK cells was virtually confined to the spleen and liver. Binding of A-NK cells to liver neoplastic tissues was observed only after i.a. injections. Conclusion This unique study design demonstrates that A-NK cells adoptively transferred to the liver via the intraarterial route have preferential access and substantial accumulation to the tumor site.
- Published
- 2006
- Full Text
- View/download PDF
4. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer
- Author
-
Luca Conti, Luca Molinaro, Francesca Maletta, Eugenio Maiorano, Sofia Asioli, Cristina Botta, Carla Pecchioni, Giuseppe Ingravallo, Luigi Chiusa, Anna Sapino, Maria Antonietta Satolli, Giuseppe Viale, M. Schena, Ludovica Verdun di Cantogno, Asioli S, Maletta F, Verdun di Cantogno L, Satolli MA, Schena M, Pecchioni C, Botta C, Chiusa L, Molinaro L, Conti L, Viale G, Ingravallo G, Maiorano E, and Sapino A
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Receptor, ErbB-2 ,medicine.medical_treatment ,In situ hybridization ,Adenocarcinoma ,HercepTest ,Specimen Handling ,Pathology and Forensic Medicine ,Stomach Neoplasms ,HER2 ,medicine ,Biomarkers, Tumor ,Humans ,Gastric cancer ,Immunohistochemistry ,Surgical specimen ,Aged ,Aged, 80 and over ,biology ,Cancer ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Prognosis ,Primary tumor ,Survival Rate ,Tissue Array Analysis ,Lymphatic Metastasis ,biology.protein ,Gastrectomy ,Female ,Lymph ,Lymph Nodes ,Antibody - Abstract
Summary Gastric cancer shows intratumoral heterogeneity for human epidermal growth factor receptor 2 expression. We evaluated whether the number of tissue blocks analyzed or the antibodies used may influence the immunohistochemical results in gastrectomy specimens. Clinicopathologic data from 148 patients receiving gastric surgery for cancer were collected. One tissue block for each of 88 primary tumors and 60 paired primary tumors and metastases was examined for human epidermal growth factor receptor 2 status by immunohistochemistry using 3 different antibodies (HercepTest, CB11, and 4B5) and by fluorescent in situ hybridization. Two additional tissue blocks of the primary tumor were tested by immunohistochemistry if the results were negative on the first tissue block. The concordance among the 3 antibodies was 94.5% (testing 1 tissue block). Two cases showed a clinically significant discrepancy between primary tumor (score 0) and lymph nodes metastases (score 3+). Additional block analysis increased both the sensitivity (from 63% to 83%) and the accuracy (from 91% to 94%) of immunohistochemistry as compared with fluorescent in situ hybridization. The multiblock approach could potentially identify a greater number of human epidermal growth factor receptor 2–positive gastric cancers, particularly those with higher levels of intratumor heterogeneity. In turn, human epidermal growth factor receptor 2 positivity correlated with a worse prognosis ( P = .011) and was an independent variable in multivariate analysis (hazard ratio, 1.57). In conclusion, testing more than 1 tissue block of cancer from specimens of gastric resection provides a more reliable human epidermal growth factor receptor 2 assessment regardless of the antibody used.
- Published
- 2012
- Full Text
- View/download PDF
5. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
- Author
-
Michelle Sterpi, Maria Antonietta Satolli, Salvatore Intagliata, Toni Ibrahim, L. Ginocchi, Bruno Vincenzi, Vincenzo Adamo, Raffaele Addeo, Alfredo Falcone, Filippo de Marinis, Giuseppe Badalamenti, Cinzia Ortega, Antonio Russo, Nicla La Verde, Flavia Longo, Daniele Santini, Gaetano Lanzetta, Davide Ottaviani, Giovanni Mansueto, Enrico Vasile, Flavia Cantile, Francesco Ferraù, Fausto Petrelli, Giuseppe Tonini, Elena Collovà, Francesca Maria Tanca, Sandro Barni, Luca Moscetti, Francesco Pantano, Andrea Mancuso, Domenico Galetta, Marco Russano, Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, and Tonini G.
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,ECOG Performance Status ,Bone Neoplasms ,Young Adult ,Internal medicine ,Carcinoma ,medicine ,80 and over ,Humans ,Young adult ,Lung cancer ,Non-Small-Cell Lung ,Aged ,Lung ,Multidisciplinary ,business.industry ,Adult, Aged, Aged, 80 and over, Bone Neoplasms, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Young Adult, Disease Progression, Multidisciplinary ,Bone metastasis ,Middle Aged ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Concomitant ,Disease Progression ,Female ,Aged, 80 and over ,Carcinoma, Non-Small-Cell Lung ,business - Abstract
We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.
- Published
- 2015
6. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey
- Author
-
Williams, Bart O., Daniele, Santini, Giuseppe, Procopio, Camillo, Porta, Toni, Ibrahim, Sandro, Barni, Calogero, Mazzara, Andrea, Fontana, Berruti, Alfredo, Rossana, Berardi, Bruno, Vincenzi, Cinzia, Ortega, Davide, Ottaviani, Giacomo, Carteni, Gaetano, Lanzetta, Vladimir, Virzì, Matteo, Santoni, Nicola, Silvestris, Maria Antonietta Satolli, Elena, Collovà, Antonio, Russo, Giuseppe, Badalamenti, Stefano Luzi Fedeli, Francesca Maria Tanca, Vincenzo, Adamo, Evaristo, Maiello, Roberto, Sabbatini, Alessandra, Felici, Saverio, Cinieri, Giuseppe, Tonini, Sergio, Bracarda, Santini, D, Procopio, G, Porta, C, Ibrahim, T, Barni, S, Mazzara, C, Fontana, A, Berruti, A, Berardi, R, Vincenzi, B, Ortega, C, Ottaviani, D, Carteni, G, Lanzetta, G, Virzì, V, Santoni, M, Silvestris, N, Satolli, MA, Collovà, E, Russo, A, Badalamenti, G, Fedeli, SL, Tanca, FM, Adamo, V, Maiello, E, Sabbatini, R, Felici, A, Cinieri, S, Tonini, G, and Bracarda, S
- Subjects
Oncology ,Male ,Anatomy and Physiology ,Bone disease ,Epidemiology ,Settore MED/06 - Oncologia Medica ,medicine.medical_treatment ,Metastasis ,bone metastases ,Renal cell carcinoma ,Basic Cancer Research ,Medicine ,Musculoskeletal System ,Multidisciplinary ,Diphosphonates ,renal cell carcinoma, bone metastasis, zoledronic acid ,Bone metastasis ,Kidney Neoplasms ,Italy ,Observational Studies ,Disease Progression ,Female ,Cancer Epidemiology ,medicine.drug ,Research Article ,medicine.medical_specialty ,Clinical Research Design ,Science ,renal cancer ,Bone Neoplasms ,Internal medicine ,Humans ,Bone ,Retrospective Studies ,business.industry ,Renal Cell Carcinoma ,Cancer ,Cancers and Neoplasms ,Bone fracture ,medicine.disease ,Surgery ,Radiation therapy ,Genitourinary Tract Tumors ,Zoledronic acid ,business - Abstract
BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; PConclusionsRCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.
- Published
- 2013
7. Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey
- Author
-
Paolo Pedrazzoli, Ferdinando Riccardi, Teresa Gamucci, Paola Bertocchi, Alessandro Comandone, Teresa Di Palma, Antonio Febbraro, Francesco Pantano, Saverio Cinieri, Rossana Berardi, Vincenzo Catalano, Maria Antonietta Satolli, Toni Ibrahim, Francesco Angelini, Amalia Azzariti, Evaristo Maiello, Anna Elisabetta Brunetti, Raimondo Ferrara, Sandro Barni, Alessandro Bertolini, Daniele Santini, Fernando De Vita, Nicola Silvestris, Antonio Russo, Salvatore Pisconti, Antonio Trogu, Silvana Leo, Elisa Giommoni, Antonio Bernardo, Silvestris, N, Pantano, F, Ibrahim, T, Gamucci, T, DE VITA, Ferdinando, Di Palma, T, Pedrazzoli, P, Barni, S, Bernardo, A, Febbraro, A, Satolli, Ma, Bertocchi, P, Catalano, V, Giommoni, E, Comandone, A, Maiello, E, Riccardi, F, Ferrara, R, Trogu, A, Berardi, R, Leo, S, Bertolini, A, Angelini, F, Cinieri, S, Russo, A, Pisconti, S, Brunetti, Ae, Azzariti, A, Santini, D., De Vita, F, Satolli, M, Brunetti, A, and Santini, D
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Pathology ,Bone disease ,Settore MED/06 - Oncologia Medica ,medicine.medical_treatment ,Science ,Bone Neoplasms ,Metastasis ,gastric cancer ,bone metastasis ,Stomach Neoplasms ,Internal medicine ,medicine ,Humans ,skeletal disease, advanced hepatocellular carcinoma,skeletal-related events, bisphosphonate ,Aged ,Bone Density Conservation Agents ,Diphosphonates ,Female ,Middle Aged ,Neoplasm Metastasis ,Patient Outcome Assessment ,Population Surveillance ,Prognosis ,Retrospective Studies ,Multidisciplinary ,business.industry ,Bone metastasis ,Cancer ,Bone fracture ,medicine.disease ,Radiation therapy ,Zoledronic acid ,Medicine ,business ,medicine.drug ,Research Article - Abstract
BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and three events, respectively. Median times to first and second SRE were 2 and 4 months, respectively. Median survival was 6 months after bone metastasis diagnosis and 3 months after first SRE. Median survival in patients who did not experience SREs was 5 months. Among patients who received zoledronic acid before the first SRE, the median time to appearance of first SRE was significantly prolonged compared to control (7 months vs 4 months for control; P: 0.0005).ConclusionsTo our knowledge, this retrospective analysis is the largest multicenter study to demonstrate that bone metastases from GC are not so rare, are commonly aggressive and result in relatively early onset of SREs in the majority of patients. Indeed, our large study, which included 90 patients treated with ZOL, showed, for the first time in literature, a significant extension of time to first SRE and increase in the median survival time after diagnosis of bone metastasis. Taken together, these data may support the beneficial effects of ZOL in GC patients.
- Published
- 2013
8. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients
- Author
-
Alfredo Berruti, Daniele Santini, Salvatore Del Prete, Maria Antonietta Satolli, Giuseppa Ferraro, Giuseppe Tonini, Ilaria Roato, Vincenzo Adamo, Antonio Russo, Gaetano Lanzetta, Raffaele Addeo, Sara Galluzzo, Filippo Montemurro, Maura Rossi, V. Leoni, Bruno Vincenzi, Mauro Antimi, Maria Rosaria Valerio, Michele Caraglia, Vittorio Fusco, Stefania Redana, Monica Marra, Santini, D, Vincenzi, B, Adamo, V, Addeo, R, Fusco, V, Russo, A, Montemurro, F, Roato, I, Redana, S, Lanzetta, G, Satolli, Ma, Berruti, A, Leoni, V, Galluzzo, S, Antimi, M, Ferraro, G, Rossi, M, DEL PRETE, S, Valerio, Mr, Marra, M, Caraglia, Michele, Tonini, G., Satolli, M, Del Salvatore, P, Valerio, MR, Caraglia, M, and Tonini, G
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Settore MED/06 - Oncologia Medica ,Antineoplastic Agents ,Breast Neoplasms ,Drug resistance ,Antibodies, Monoclonal, Humanized ,Metastasis ,Breast Neoplasms, Male ,Antineoplastic Agent ,Cohort Studies ,Breast cancer ,Retrospective Studie ,Trastuzumab ,Internal medicine ,medicine ,Humans ,skin and connective tissue diseases ,Metastatic breast cancer ,Smoking ,Aged ,Aged, 80 and over ,Antibodies, Monoclonal ,Drug Resistance, Neoplasm ,Female ,Middle Aged ,Retrospective Studies ,neoplasms ,Gynecology ,business.industry ,Cancer ,Retrospective cohort study ,General Medicine ,medicine.disease ,trastuzumab, smoking, metastatic breast cancer ,metastatic breast cancer ,Breast disease ,Cohort Studie ,business ,Breast Neoplasm ,Human ,medicine.drug - Abstract
Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients. Copyright © 2011 Spandidos Publications Ltd. All rights reserved.
- Published
- 2011
9. HER2 assessment in gastric cancer: proposal of a work-flow for practical routine use
- Author
-
ASIOLI, SOFIA, Maletta F., Verdun di Cantogno L., Satolli M.A., Schena M., Pecchioni C., Botta C., D’Angelo G., Recupero D., Sapino A., Asioli S., Maletta F., Verdun di Cantogno L., Satolli MA., Schena M., Pecchioni C., Botta C., D’Angelo G., Recupero D., and Sapino A.
- Subjects
HER2 ,stomach - Abstract
Background. In gastric cancer (GC) the expression of HER2 is known as a marker of prognosis and recently it has been confirmed as a predictive marker of response to trastuzumab. Methods. GC specimens of 42 patients were collected. Representative samples from both primary tumors (42 samples) and lymph node metastases (23 samples), were selected. In each case, 4B5 (Ventana), CB11 (kit Oracle Menarini), HercepTest (Dako) antibodies were tested in immunohistochemistry (IHC) and scored as proposed for GC. HER2 gene status was studied by double probe fluorescence in situ hybridization (FISH) in all cases. Concordance among IHC scoring results of the 3 antibodies and between FISH results and IHC (0/1+ and 2+/3+), independently from the percentage of positive cells, were evaluated using the Cohen-Fleiss’ kappa statistic (K). Then, the number of specimens needed to be tested in cases with < 10% of HER2 overexpression was assessed. Finally, influence of gain of CEP17 (copies number > 3) on the results of FISH ratio was considered. Results. The 3 antibodies showed a K of 0,76 (p < 0,05). In the primary tumor, the overall concordance of FISH/IHC, taking into account the results of at least one antibody, was of 0,95 (p < 0,05). FISH/IHC concordance decreased to 0,82 (p < 0,05) when correlated with lymph node metastases. Five cases showed 2+/3+ score values in < 10% of cells. In 4 of these cases the percentage increased to > 10% adding 2 more sections from different tissue blocks of the primary tumor. In our results, the gain of CEP17 did not influence the final score ratio of FISH analysis. In conclusions, the HER2 analysis in GC needs a specific protocol avoiding working over-load and to solve equivocal cases.
- Published
- 2010
10. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens.
- Author
-
Brugiapaglia S, Bulfamante S, Curcio C, Arigoni M, Calogero R, Bonello L, Genuardi E, Spadi R, Satolli MA, Campra D, Giordano D, Cappello P, Cordero F, and Novelli F
- Subjects
- Humans, Male, Female, Transcriptome, Aged, Middle Aged, T-Lymphocytes immunology, T-Lymphocytes metabolism, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Phosphopyruvate Hydratase genetics, Phosphopyruvate Hydratase immunology, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell metabolism, Receptors, Antigen, T-Cell immunology, Pancreatic Neoplasms immunology, Pancreatic Neoplasms therapy, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Antigens, Neoplasm immunology, Antigens, Neoplasm genetics, Carcinoma, Pancreatic Ductal therapy, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal drug therapy
- Abstract
Introduction: Pancreatic Ductal Adenocarcinoma (PDA) is one of the most aggressive malignancies with a 5-year survival rate of 13%. Less than 20% of patients have a resectable tumor at diagnosis due to the lack of distinctive symptoms and reliable biomarkers. PDA is resistant to chemotherapy (CT) and understanding how to gain an anti-tumor effector response following stimulation is, therefore, critical for setting up an effective immunotherapy., Methods: Proliferation, and cytokine release and TCRB repertoire of from PDA patient peripheral T lymphocytes, before and after CT, were analyzed in vitro in response to four tumor-associated antigens (TAA), namely ENO1, FUBP1, GAPDH and K2C8. Transcriptional state of PDA patient PBMC was investigated using RNA-Seq before and after CT., Results: CT increased the number of TAA recognized by T lymphocytes, which positively correlated with patient survival, and high IFN-γ production TAA-induced responses were significantly increased after CT. We found that some ENO1-stimulated T cell clonotypes from CT-treated patients were expanded or de-novo induced, and that some clonotypes were reduced or even disappeared after CT. Patients that showed a higher number of effector responses to TAA (high IFN-γ/IL-10 ratio) after CT expressed increased fatty acid-related transcriptional signature. Conversely, patients that showed a higher number of regulatory responses to TAA (low IFN-γ/IL-10 ratio) after CT significantly expressed an increased IRAK1/IL1R axis-related transcriptional signature., Conclusion: These data suggest that the expression of fatty acid or IRAK1/IL1Rrelated genes predicts T lymphocyte effector or regulatory responses to TAA in patients that undergo CT. These findings are a springboard to set up precision immunotherapies in PDA based on the TAA vaccination in combination with CT., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Brugiapaglia, Bulfamante, Curcio, Arigoni, Calogero, Bonello, Genuardi, Spadi, Satolli, Campra, Giordano, Cappello, Cordero and Novelli.)
- Published
- 2024
- Full Text
- View/download PDF
11. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
- Author
-
Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, and Casadei-Gardini A
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, Middle Aged, Adult, Aged, 80 and over, Gemcitabine, Cisplatin therapeutic use, Cisplatin pharmacology, Cisplatin administration & dosage, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Deoxycytidine pharmacology, Deoxycytidine administration & dosage, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal administration & dosage
- Abstract
Background: The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed cell death ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC)., Objective: The present study investigated for the first time the impact on survival of adding durvalumab to cisplatin/gemcitabine compared with cisplatin/gemcitabine in a real-world setting., Patients and Methods: The analyzed population included patients with unresectable, locally advanced, or metastatic BTC treated with durvalumab in combination with cisplatin/gemcitabine or with cisplatin/gemcitabine alone. The impact of adding durvalumab to chemotherapy in terms of overall survival (OS) and progression free survival (PFS) was investigated with univariate and multivariate analysis., Results: Overall, 563 patients were included in the analysis: 213 received cisplatin/gemcitabine alone, 350 received cisplatin/gemcitabine plus durvalumab. At the univariate analysis, the addition of durvalumab was found to have an impact on survival, with a median OS of 14.8 months versus 11.2 months [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.50-0.80, p = 0.0002] in patients who received cisplatin/gemcitabine plus durvalumab compared to those who received cisplatin/gemcitabine alone. At the univariate analysis for PFS, the addition of durvalumab to cisplatin/gemcitabine demonstrated a survival impact, with a median PFS of 8.3 months and 6.0 months (HR 0.57, 95% CI 0.47-0.70, p < 0.0001) in patients who received cisplatin/gemcitabine plus durvalumab and cisplatin/gemcitabine alone, respectively. The multivariate analysis confirmed that adding durvalumab to cisplatin/gemcitabine is an independent prognostic factor for OS and PFS, with patients > 70 years old and those affected by locally advanced disease experiencing the highest survival benefit. Finally, an exploratory analysis of prognostic factors was performed in the cohort of patients who received durvalumab: neutrophil-lymphocyte ratio (NLR) and disease stage were to be independent prognostic factors in terms of OS. The interaction test highlighted NLR ≤ 3, Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 0, and locally advanced disease as positive predictive factors for OS on cisplatin/gemcitabine plus durvalumab., Conclusion: In line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced BTC., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
12. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival.
- Author
-
Curcio C, Rosso T, Brugiapaglia S, Guadagnin G, Giordano D, Castellino B, Satolli MA, Spadi R, Campra D, Moro F, Papotti MG, Bertero L, Cassoni P, De Angelis C, Langella S, Ferrero A, Armentano S, Bellotti G, Fenocchio E, Nuzzo A, Ciccone G, and Novelli F
- Subjects
- Humans, Prognosis, Autoantibodies metabolism, Biomarkers, Tumor metabolism, Phosphopyruvate Hydratase, DNA-Binding Proteins, Tumor Suppressor Proteins metabolism, RNA-Binding Proteins, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms pathology, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal pathology
- Abstract
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis due to a lack of early diagnostic markers and effective therapy. In PDA patients, the glycolytic enzyme and plasminogen receptor alpha-enolase (ENO1) and the transcription factor far upstream element-binding protein 1 (FUBP1) are upregulated and elicit the production of autoantibodies (aAb) that discriminate healthy subjects from PDA patients, with the latter mostly directed to post-translational phosphorylated isoforms. Here, the correlation of prognosis with circulating ENO1 and FUBP1aAb, and their protein tissue expression was analyzed in PDA patients. Circulating ENO1 and FUBP1 aAb was analyzed in two cohorts of PDA patients by ELISA (n = 470), while tissues expression was observed by immunohistochemistry (n = 45). Overall survival (OS) was estimated using the Kaplan-Meier method, while the Cox model was used to estimate the hazard ratios (HR) adjusted for the main prognostic factors. Logistic models were applied to assess associations between death and its risk indicators. All statistical analyses were performed with Stata version 15. Unlike ENO1 aAb, there was a significant correlation between FUBP1 aAb and FUBP1 expression in tumors (p = 0.0268). In addition, we found that high ENO1 (p = 0.016) and intermediate FUBP1 aAb levels (p = 0.013) were unfavorable prognostic factors. Notably, it was found that high anti-FUBP1 aAb level is a good prognostic marker for tail-body PDA (p = 0.016). Our results suggest that different levels of circulating aAb to ENO1 and FUBP1 predict a poor outcome in PDA patients and can be used to improve therapeutic strategies., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
13. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
- Author
-
Procaccio L, Merz V, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, Pinto C, Zecchetto C, Barsotti G, De Vita F, Milella M, Antonuzzo L, Scartozzi M, Zaniboni A, Spadi R, Casalino S, Bergamo F, De Toni C, Melisi D, and Lonardi S
- Subjects
- Humans, Middle Aged, Irinotecan, Leucovorin adverse effects, Fluorouracil adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Gemcitabine, Continuity of Patient Care, Camptothecin, Pancreatic Neoplasms, Pancreatic Neoplasms pathology, Adenocarcinoma drug therapy
- Abstract
Background: The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy. This study aims to explore the real-world efficacy and safety of 5-FU/LV-nal-IRI., Methods: This is a retrospective multicenter analysis including advPDAC patients receiving 5-FU/LV-nal-IRI after failure of gemcitabine-based therapy. Survival analyses were performed using Kaplan-Meier method, univariate and multivariate analyses by Cox regression., Results: A total of 296 patients (median age 64.4 years, ECOG PS ≥1 in 56% of cases) were treated at 11 Italian institutions between 2016 and 2018. 34% of them underwent primary tumor resection, and 79% received gemcitabine-nabpaclitaxel as first line. 5-FU/LV-nal-IRI was administered as second-line in 73% of cases. Objective response and disease control rate were 12% and 41%, respectively. Treatment was well tolerated with dose reductions in 50% of patients but no one permanent discontinuation; the commonest grade ≥3 toxicities were neutropenia (14%) and diarrhea (12%). Median PFS and OS from 5-FU/LV-nal-IRI initiation was 3.2 and 7.1 months, respectively., Conclusions: These real-world data confirm the 5-FU/LV-nal-IRI efficacy and safety in advPDAC patients progressed to gemcitabine-based therapy, with outcomes comparable to NAPOLI-1, even in a less-selected population and with more modern therapeutic algorithm., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
14. Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy.
- Author
-
Casadei-Gardini A, Leone F, Brandi G, Scartozzi M, Silvestris N, Santini D, Faloppi L, Aglietta M, Satolli MA, Rizzo A, Lonardi S, Aprile G, and Fornaro L
- Abstract
Cholangiocarcinoma is a rare group of tumors that involve the hepatic biliary tree. Prognosis for patients with cholangiocarcinoma remains dismal. Herein, we present survival trends over a long time period spanning almost 20 years in patients with advanced cholangiocarcinoma receiving systemic chemotherapy. We retrospectively analyzed a large multicenter dataset of cholangiocarcinoma outpatients evaluated in 14 centers within the Cholangiocarcinoma Italian Group Onlus (Gruppo Italiano Colangiocarcinoma Onlus, G.I.C.O.) between 2000 and 2017 (first-line), and 2002 and 2017 (second-line). Three time periods were considered: 2000-2009, 2010-2013, and 2014-2017. A total of 922 patients (51.19% male) with cholangiocarcinoma undergoing first-line therapy were evaluated. The median durations of follow-up for progression-free survival (PFS) and overall survival (OS) were 37 and 57 months, respectively. PFS at 12 months in the three periods of starting first-line therapy was similar, ranging from 11.71% to 15.25%. OS at 12 months progressively improved (38.30%, 44.61% and 49.52%, respectively), although the differences were not statistically significant after adjusting for age, disease status, and primary tumor site. A total of 410 patients (48.5% male) underwent second-line chemotherapy. The median durations of follow-up for PFS and OS were 47.6 and 41.90 months, respectively. An OS of 24.3%, 32.3%, and 33.1% was observed in 2002-2009, 2010-2013, and 2014-2017, respectively. Despite incremental benefits across years, our clinical experience confirms that modest overall advances have been achieved with first- and second-line chemotherapy in advanced cholangiocarcinoma. Efforts should focus on the identification of patients who derive the greatest benefit from treatment., Competing Interests: FL: Advisory board participation for Merck Serono, Servier, Amgen, BMS, AstraZeneca. LFo: Advisory board participation and consulting for AstraZeneca, MSD, Tahio Oncology, BMS, EliLilly, Servier, Daiichi Sankyo. GB: Advisory board participation, consulting, or research funding from Incyte, Tahio, Ipsen, and Incyte. MS: Advisory board participation or research funding MERCK, MSD, Amgen, Servier, Eisai, GSK, Astra-Zeneca, Sanofi. NS: Advisory board participation for Servier, Lilly, Roche, Eisai. SL: Advisory board participation, consulting, or research funding (institutional) from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Hutchinson, Incyte, Lilly, Merck Serono, Nirati, MSD, Pierre-Fabre, Pfizer, Roche, Servier. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Casadei-Gardini, Leone, Brandi, Scartozzi, Silvestris, Santini, Faloppi, Aglietta, Satolli, Rizzo, Lonardi, Aprile and Fornaro.)
- Published
- 2023
- Full Text
- View/download PDF
15. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy.
- Author
-
Rimini M, Casadei-Gardini A, Brandi G, Leone F, Fornaro L, Pella N, Silvestris N, Montagnani F, Lonardi S, Lai E, Galizia E, Santini D, Palloni A, Filippi R, Masi G, Aprile G, Aglietta M, Frega G, Fenocchio E, Vivaldi C, Satolli MA, Salani F, Scartozzi M, Faloppi L, Pellino A, Sperti E, Burgio V, Ratti F, Aldrighetti L, Cascinu S, and Cucchetti A
- Subjects
- Male, Humans, Cisplatin, Disease-Free Survival, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hospitals, Deoxycytidine, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology
- Abstract
Biliary tract cancer's (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians' confidence in the use of new technologies and molecular analysis turned out to be of interest and potentially influencing survival. After applying a random-effect model, the relationship between each clinical variable on the main outcome was investigated through multilevel mixed-effects logistic regression. The risk-standardized outcomes were calculated for each centre involved. In the unadjusted cohort the median survival was 8.6 months (95%C.I.: 7.8-9.3) with a 9-month survival rate of 48.3% (95%C.I.: 45.0-51.5). A substantial heterogeneity across hospitals was found (I
2 : 70.3%). In multilevel mixed effect logistic regression, male, being treated for gallbladder cancer, higher ECOG, increased NLR, CEA and Ca 19.9 and low value of haemoglobin showed to increase the odds for 9-month mortality. The model estimated that the residual variance observed in 9-month mortality was attributable for the 2.6% to the treating hospital. Through a multilevel mixed effect model, average risk-standardized mortality within 9 months was 50.1%. As noticeable, all hospital's risk-standardized mortality falls within 95%C.I., thus all participating centres provided similar outcomes when adjusted for patient case-mix. Heterogenicity between hospital did not affect the outcome in term of overall survival.- Published
- 2022
- Full Text
- View/download PDF
16. Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis.
- Author
-
Parisi A, Giampieri R, Mammarella A, Felicetti C, Salvatore L, Bensi M, Maratta MG, Strippoli A, Filippi R, Satolli MA, Petrillo A, Daniele B, De Tursi M, Di Marino P, Giordano G, Landriscina M, Vitale P, Zurlo IV, Dell'Aquila E, Tomao S, Depetris I, Di Pietro FR, Zoratto F, Ciardiello D, Pensieri MV, Garrone O, Galassi B, Ferri C, Berardi R, and Ghidini M
- Abstract
Aim: The aim of the current study is to investigate the impact of primary compared to secondary chemotherapy-induced nausea and vomiting (CINV) prophylaxis with NK1 receptor antagonists (NK1-RA) in patients affected by gastrointestinal malignancies and treated with oxaliplatin- and/or irinotecan-based doublet or triplet regimens., Study Design and Methods: Clinical data of patients affected by gastrointestinal malignancies, treated with an oxaliplatin and/or irinotecan-based doublet or triplet regimen as neo/adjuvant or advanced-line treatment, and who received NK1-RA as primary (from the first cycle of treatment) or secondary (after the onset of CINV with a previous regimen with 5HT3-RA and dexamethasone) prophylaxis for CINV, were retrospectively collected in an observational study involving 16 Italian centers. A propensity score matching was performed by taking into account the following stratification factors: sex (male vs. female), age (< vs. ≥70 years old), overweight (body mass index, BMI < vs. ≥25), underweight (BMI < vs. ≥19), disease spread (early vs. advanced/metastatic), tumor type (esophagogastric cancer vs. the rest, hepatobiliary tumor vs. the rest, colorectal cancer vs. the rest), type of NK1-RA used as primary/secondary prophylaxis (netupitant-palonosetron vs. fosaprepitant/aprepitant), concomitant use of opioids (yes vs. no), concomitant use of antidepressant/antipsychotic drugs (yes vs. no), Eastern Cooperative Oncology Group (ECOG) performance status at the start of NK1-RA treatment (0 vs. 1-2), and intensity of chemotherapy regimen (doublet vs. triplet)., Results: Among 409 patients included from January 2015 to January 2022 and eligible for analysis, 284 (69%) and 125 (31%) were treated with NK1-RA as primary and secondary antiemetic prophylaxis, respectively. After matching, primary NK1-RA use was not associated with higher rates of protection from emesis regardless the emesis phase (acute phase, p = 0.34; delayed phase, p = 0.14; overall phase, p = 0.80). On the other hand, a lower rate of relevant nausea (p = 0.02) and need for rescue antiemetic therapy (p = 0.000007) in the overall phase was found in primary NK1-RA users. Furthermore, a higher rate of both complete antiemetic response (p = 0.00001) and complete antiemetic protection (p = 0.00007) in the overall phase was more frequently observed in primary NK1-RA users. Finally, chemotherapy delays (p = 0.000009) and chemotherapy dose reductions (p = 0.0000006) were less frequently observed in primary NK1-RA users., Conclusion: In patients affected by gastrointestinal malignancies, a primary CINV prophylaxis with NK1-RA, 5HT3-RA, and dexamethasone might be appropriate, particularly in those situations at higher risk of emesis and in which it is important to avoid dose delays and/or dose reductions, keeping a proper dose intensity of chemotherapy drugs., Competing Interests: APa reported receiving advisory board fees from GSK, Servier, Pharmamar. RG reported receiving fees from Amgen and Servier and advisory board fees from Amgen, Servier, Bayer and Merck-Serono. LS reported receiving fees from Pierre-Fabre, AstraZeneca, Bayer, Servier, Merck, Amgen. APe reported receiving fees from Eli-Lilly, MSD, BMS, Merck, Servier. BD has received fees from Ipsen, Eisai, Eli Lilly, AstraZeneca, Sanofi, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Bayer, Roche, and Amgen; and has received non-financial support from Ipsen, BMS. MG reported receiving fees by Amgen, Merck, Eli-Lilly, Servier, Italfarmaco. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Parisi, Giampieri, Mammarella, Felicetti, Salvatore, Bensi, Maratta, Strippoli, Filippi, Satolli, Petrillo, Daniele, De Tursi, Di Marino, Giordano, Landriscina, Vitale, Zurlo, Dell’Aquila, Tomao, Depetris, Di Pietro, Zoratto, Ciardiello, Pensieri, Garrone, Galassi, Ferri, Berardi and Ghidini.)
- Published
- 2022
- Full Text
- View/download PDF
17. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
- Author
-
Filippi R, Leone F, Fornaro L, Aprile G, Casadei-Gardini A, Silvestris N, Palloni A, Satolli MA, Scartozzi M, Russano M, Lutrino SE, Lombardi P, Frega G, Garattini SK, Vivaldi C, Spadi R, Giulia O, Fenocchio E, Brunetti O, Aglietta M, and Brandi G
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Neoplasm Recurrence, Local drug therapy, Prognosis, Prospective Studies, Retrospective Studies, Treatment Outcome, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology
- Abstract
Advanced biliary tract cancer (aBTC) comprises a heterogeneous group of rare malignancies with dismal prognosis. Given the scarcity of prospective evidence, the aim of this study was to derive clinically useful insights and prognostic factors from a large, real-world series of aBTC. Clinicopathologic variables and treatment outcomes were retrospectively collected involving 940 patients diagnosed with aBTC between 2001 and 2017, and treated with first-line chemotherapy (CT1) at 14 Italian medical oncology institutions. Median overall survival (OS) was 10.3 months (CI
95% 9.5-11.1). CT1 with gemcitabine-Platinum salts doublets achieved OS of 11.7 months vs 7.5 with gemcitabine alone (HR 0.67, p < 0.001). However, a clear temporal trend towards improved OS could not be demonstrated. Radical surgery of recurrent disease achieved a relapse-free survival of 5.9 months. A substantial minority (44.5%) of patients were able to receive a second-line chemotherapy, which achieved a response rate of 7.6%, and disease control in 30% of patients with no significant differences between combination regimens and monotherapies. In a large retrospective series of real-world aBTC, outcomes of standard CT1 closely resembled those of the registrational trials. A limited set of easily retrievable independent prognostic factors was defined. Further research is needed on second-line regimens.- Published
- 2022
- Full Text
- View/download PDF
18. Results of the observational prospective RealFLOT study.
- Author
-
Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, and Antonuzzo L
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma mortality, Adenocarcinoma surgery, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Docetaxel administration & dosage, Docetaxel adverse effects, Feasibility Studies, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Italy, Male, Microsatellite Instability, Middle Aged, Neutropenia chemically induced, Oxaliplatin administration & dosage, Oxaliplatin adverse effects, Prognosis, Prospective Studies, Stomach Neoplasms genetics, Stomach Neoplasms mortality, Stomach Neoplasms surgery, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophagogastric Junction, Stomach Neoplasms drug therapy
- Abstract
Background: Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone., Methods: RealFLOT is an Italian, multicentric, observational trial, collecting data from patients with resectable GC or GEJ adenocarcinoma treated with perioperative FLOT. Aim of the study was to describe feasibility and safety of FLOT, pathological complete response rate (pCR), surgical outcomes and overall response rate (ORR) in an unselected real-world population. Additional analyses evaluated the correlation between pCR and survival and the prognostic role of microsatellite instability (MSI) status., Results: Of 206 patients enrolled that received perioperative FLOT at 15 Italian centers, 124 (60.2%) received at least 4 full-dose cycles, 190 (92.2%) underwent surgery, and 142 (68.9%) started the postoperative phase. Among patients who started the postoperative phase, 105 (51.0%) received FLOT, while 37 (18%) received de-intensified regimens, depending on clinical condition or previous toxicities. pCR was achieved in 7.3% of cases. Safety profile was consistent with literature. Neutropenia was the most common G 3-4 adverse event (AE): 19.9% in the preoperative phase and 16.9% in the postoperative phase. No toxic death was observed and 30-day postoperative mortality rate was 1.0%. ORR was 45.6% and disease control rate (DCR) was 94.2%. Disease-free survival (DFS) and OS were significantly longer in case of pCR (p = 0.009 and p = 0.023, respectively). A trend towards better DFS was observed among MSI-H patients., Conclusions: These real-world data confirm the feasibility of FLOT in an unselected population, representative of the clinical practice. pCR rate was lower than expected, nevertheless we confirm pCR as a predictive parameter of survival. In addition, MSI-H status seems to be a positive prognostic marker also in patients treated with taxane-containing triplets., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
19. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
- Author
-
Filippi R, Montagnani F, Lombardi P, Fornaro L, Aprile G, Casadei-Gardini A, Faloppi L, Palloni A, Satolli MA, Scartozzi M, Citarella F, Lutrino SE, Vivaldi C, Silvestris N, Rovesti G, Rimini M, Aglietta M, Brandi G, and Leone F
- Subjects
- Antineoplastic Combined Chemotherapy Protocols, Humans, Lymphocytes, Prognosis, Retrospective Studies, Bile Duct Neoplasms, Biliary Tract Neoplasms drug therapy
- Abstract
Background: Standard treatment of advanced biliary tract cancer (aBTC) is represented by first-line chemotherapy (CT1). However, some patients do not gain any benefit from CT1, contributing to the overall dismal prognosis of aBTC. The present study aimed to devise a prognostic model in aBTC patients receiving CT1., Methods: A large panel of clinical, laboratory, and pathology variables, available before the start of CT1, were retrospectively assessed in a multi-centric cohort to determine their prognostic value on univariate and multivariate regression analysis. The variables that showed a significant correlation with overall survival (OS) were computed in a three-tier prognostic score. External validation of the prognostication performance was carried out., Results: Clinical histories of 935 patients (median OS 10.3 months), with diagnosis dates ranging from 2001 to 2017, were retrieved from 14 institutions. According to multivariate analysis, Eastern Cooperative Oncology Group performance status, carbohydrate antigen 19.9, albumin levels, and neutrophil/lymphocyte ratio were strongly associated with OS ( p <0.01). The prognostic score could generate a highly significant stratification (all between-group p values ≤0.001) into groups of favorable (comprising 51.5% of the sample), intermediate (39.2%), and poor prognosis (9.3%): median OS was 12.7 (CI
95% 11.0-14.4), 7.1 (CI95% 5.8-8.4), and 3.2 months (CI95% 1.7-4.7), respectively. This OS gradient was replicated in the validation set (129 patients), with median OS of 12.7 (CI95% 11.0-14.3), 7.5 (CI95% 6.1-8.9), and 1.4 months (CI95% 0.1-2.7), respectively (all between-group p values ≤0.05)., Conclusion: A prognostic score, derived from a limited set of easily-retrievable variables, efficiently stratified a large population of unselected aBTC patients undergoing CT1. This tool could be useful to clinicians, to ascertain the potential benefit from CT1 at the start of treatment.- Published
- 2021
- Full Text
- View/download PDF
20. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
- Author
-
Filippi R, Depetris I, and Satolli MA
- Subjects
- Adult, Child, Gene Fusion, Humans, Oncogene Proteins, Fusion genetics, Pyrazoles, Pyrimidines, Neoplasms drug therapy, Neoplasms genetics, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use
- Abstract
Introduction : Characteristic of some rare pediatric and adult malignancies, addiction to the NTRK oncogene family is also observed in a small fraction of common cancers. Inhibition of their protein products, the Trk kinases, proved a successful treatment strategy for these tumors. Areas covered : The current paper reviews the clinical development of larotrectinib, a selective inhibitor of the Trk kinase family, for the treatment of NTRK fusion-positive cancers. The manuscript includes an overview of the efficacy, safety, pharmacokinetics and pharmacodynamics. The authors sum up by providing the reader with their expert opinion on larotrectinib and its potential future use. Expert opinion : Larotrectinib showed tolerability and high efficacy, regardless of the primary site. In 2018, larotrectinib was granted by the Food and Drug Administration a tissue-agnostic approval for the treatment of solid tumors harboring an NTRK fusion. The major challenges will be the implementation of the screening for NTRK fusions in the general oncologic population, and the incorporation of larotrectinib into the therapeutic algorithms.
- Published
- 2021
- Full Text
- View/download PDF
21. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions.
- Author
-
Mucciolo G, Curcio C, Roux C, Li WY, Capello M, Curto R, Chiarle R, Giordano D, Satolli MA, Lawlor R, Scarpa A, Lukac P, Stakheev D, Provero P, Vannucci L, Mak TW, Novelli F, and Cappello P
- Subjects
- Adenocarcinoma pathology, Animals, CD8-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes pathology, Cancer-Associated Fibroblasts metabolism, Cancer-Associated Fibroblasts pathology, Carcinogenesis genetics, Carcinoma, Pancreatic Ductal pathology, Disease Models, Animal, Forkhead Transcription Factors genetics, Humans, Mice, Mice, Knockout, Tumor Microenvironment genetics, Adenocarcinoma genetics, Carcinoma, Pancreatic Ductal genetics, Interleukin-17 genetics, Receptors, Interleukin genetics
- Abstract
A hallmark of cancer, including pancreatic ductal adenocarcinoma (PDA), is a massive stromal and inflammatory reaction. Many efforts have been made to identify the anti- or protumoral role of cytokines and immune subpopulations within the stroma. Here, we investigated the role of interleukin-17A (IL17A) and its effect on tumor fibroblasts and the tumor microenvironment. We used a spontaneous PDA mouse model (KPC) crossed to IL17A knockout mice to show an extensive desmoplastic reaction, without impaired immune infiltration. Macrophages, especially CD80
+ and T cells, were more abundant at the earlier time point. In T cells, a decrease in FoxP3+ cells and an increase in CD8+ T cells were observed in KPC/IL17A-/- mice. Fibroblasts isolated from IL17A+/+ and IL17A-/- KPC mice revealed very different messenger RNA (mRNA) and protein profiles. IL17A-/- fibroblasts displayed the ability to restrain tumor cell invasion by producing factors involved in extracellular matrix remodeling, increasing T cell recruitment, and producing higher levels of cytokines and chemokines favoring T helper 1 cell recruitment and activation and lower levels of those recruiting myeloid/granulocytic immune cells. Single-cell quantitative PCR on isolated fibroblasts confirmed a very divergent profile of IL17A-proficient and -deficient cells. All these features can be ascribed to increased levels of IL17F observed in the sera of IL17A-/- mice, and to the higher expression of its cognate receptor (IL17RC) specifically in IL17A-/- cancer-associated fibroblasts (CAFs). In addition to the known effects on neoplastic cell transformation, the IL17 cytokine family uniquely affects fibroblasts, representing a suitable candidate target for combinatorial immune-based therapies in PDA., Competing Interests: The authors declare no competing interest.- Published
- 2021
- Full Text
- View/download PDF
22. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination.
- Author
-
Mandili G, Curcio C, Bulfamante S, Follia L, Ferrero G, Mazza E, Principe M, Cordero F, Satolli MA, Spadi R, Evangelista A, Giordano D, Viet D, Cappello P, and Novelli F
- Subjects
- Aged, Animals, Female, Humans, Mice, Middle Aged, Vaccines, DNA pharmacology, Antigens, Neoplasm immunology, Carcinoma, Pancreatic Ductal drug therapy, Immunotherapy methods, Proteomics methods, Vaccines, DNA therapeutic use
- Abstract
Background: Pancreatic ductal adenocarcinoma (PDA) is an almost incurable tumor that is mostly resistant to chemotherapy (CT). Adaptive immune responses to tumor-associated antigens (TAA) have been reported, but immunotherapy (IT) clinical trials have not yet achieved any significant increase in survival, confirming the suppressive environment of PDA. As CT has immune-modulating properties, we investigated the effect of gemcitabine (GEM) in antitumor effector responses to TAA in patients with PDA., Methods: The IgG antibody repertoire in patients with PDA before and after CT was profiled by serological proteome analysis and ELISA and their ability to activate complement-dependent cytotoxicity (CDC) was measured. Peripheral T cells were stimulated in vitro with recombinant TAA, and specific proliferation, IFN-γ/IL-10 and CD8
+ /Treg ratios were measured. Mice that spontaneously developed PDA were treated with GEM and inoculated with an ENO1 (α-Enolase) DNA vaccine. In some experimental groups, the effect of depleting CD4, CD8 and B cells by specific antibodies was also evaluated., Results: CT increased the number of TAA recognized by IgG and their ability to activate CDC. Evaluation of the IFN-γ/IL-10 ratio and CD8+/Treg ratios revealed that CT treatment shifted T cell responses to ENO1, G3P (glyceraldheyde-3-phosphate dehydrogenase), K2C8 (keratin, type II cytoskeletal 8) and FUBP1 (far upstream binding protein 1), four of the most recognized TAA, from regulatory to effector. In PDA mice models, treatment with GEM prior to ENO1 DNA vaccination unleashed CD4 antitumor activity and strongly impaired tumor progression compared with mice that were vaccinated or GEM-treated alone., Conclusions: Overall, these data indicate that, in PDA, CT enhances immune responses to TAA and renders them suitable targets for IT., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2020
- Full Text
- View/download PDF
23. Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients.
- Author
-
Mandili G, Follia L, Ferrero G, Katayama H, Hong W, Momin AA, Capello M, Giordano D, Spadi R, Satolli MA, Evangelista A, Hanash SM, Cordero F, and Novelli F
- Abstract
Pancreatic Ductal Adenocarcinoma (PDA) is an aggressive malignancy with a very poor outcome. Although chemotherapy (CT) treatment has poor efficacy, it can enhance tumor immunogenicity. Tumor-Associated Antigens (TAA) are self-proteins that are overexpressed in tumors that may induce antibody production and can be PDA theranostic targets. However, the prognostic value of TAA-antibody association as Circulating Immune Complexes (CIC) has not yet been elucidated, mainly due to the lack of techniques that lead to their identification. In this study, we show a novel method to separate IgG, IgM, and IgA CIC from sera to use them as prognostic biomarkers of CT response. The PDA Immune-Complexome (IC) was identified using a LTQ-Orbitrap mass spectrometer followed by computational analysis. The analysis of the IC of 37 PDA patients before and after CT revealed differential associated antigens (DAA) for each immunoglobulin class. Our method identified different PDA-specific CIC in patients that were associated with poor prognosis patients. Finally, CIC levels were significantly modified by CT suggesting that they can be used as effective prognostic biomarkers to follow CT response in PDA patients.
- Published
- 2020
- Full Text
- View/download PDF
24. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
- Author
-
Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, and Montagnani F
- Subjects
- Adult, Aged, Female, Fluorouracil administration & dosage, Follow-Up Studies, Humans, Irinotecan administration & dosage, Male, Middle Aged, Numerical Analysis, Computer-Assisted, Oxaliplatin administration & dosage, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Prognosis, Retrospective Studies, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Nomograms, Pancreatic Neoplasms mortality
- Abstract
Background: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcomes., Patients and Methods: We investigated putative prognostic factors among 137 MPC/LAPC patients treated with triplet chemotherapy. Association with 6-month survival status (primary endpoint) was assessed by multivariate logistic regression models. A nomogram predicting the risk of death at 6 months was built by assigning a numeric score to each identified variable, weighted on its level of association with survival. External validation was performed in an independent data set of 206 patients. The study was registered at ClinicalTrials.gov (NCT03590275)., Results: Four variables (performance status, liver metastases, baseline carbohydrate antigen 19-9 level, and neutrophil-to-lymphocyte ratio) were found to be associated with 6-month survival by multivariate analysis or had sufficient clinical plausibility to be included in the nomogram. Accuracy was confirmed in the validation cohort (C index = 0.762; 95% confidence interval, 0.713-0.825). After grouping all cases, 4 subsets with different outcomes were identified by 0, 1, 2, or > 2 poor prognostic features (P < .0001)., Conclusion: The nomogram we constructed accurately predicts the risk of death in the first 6 months after initiation of FOLFIRINOX in MPC/LAPC patients. This tool could be useful to guide communication about prognosis, and to inform the design and interpretation of clinical trials., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
25. Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.
- Author
-
Follia L, Ferrero G, Mandili G, Beccuti M, Giordano D, Spadi R, Satolli MA, Evangelista A, Katayama H, Hong W, Momin AA, Capello M, Hanash SM, Novelli F, and Cordero F
- Abstract
Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a curative surgical resection. For this reason there is an urgent need for personalized therapies. PDA is the result of complex interactions between tumor molecular profile and metabolites produced by its microenvironment. Despite recent studies identified PDA molecular subtypes, its metabolic classification is still lacking. Methods: We applied an integrative analysis on transcriptomic and genomic data of glycolytic genes in PDA. Data were collected from public datasets and molecular glycolytic subtypes were defined using hierarchical clustering. The grade of purity of the cancer samples was assessed estimating the different amount of stromal and immunological infiltrate among the identified PDA subtypes. Analyses of metabolomic data from a subset of PDA cell lines allowed us to identify the different metabolites produced by the metabolic subtypes. Sera of a cohort of 31 PDA patients were analyzed using Q-TOF mass spectrometer to measure the amount of metabolic circulating proteins present before and after chemotherapy. Results: Our integrative analysis of glycolytic genes identified two glycolytic and two non-glycolytic metabolic PDA subtypes. Glycolytic patients develop disease earlier, have poor prognosis, low immune-infiltrated tumors, and are characterized by a gain in chr12p13 genomic region. This gain results in the over-expression of GAPDH, TPI1 , and FOXM1 . PDA cell lines with the gain of chr12p13 are characterized by an higher lipid uptake and sensitivity to drug targeting the fatty acid metabolism. Our sera proteomic analysis confirms that TPI1 serum levels increase in poor prognosis gemcitabine-treated patients. Conclusions: We identify four metabolic PDA subtypes with different prognosis outcomes which may have pivotal role in setting personalized treatments. Moreover, our data suggest TPI1 as putative prognostic PDA biomarker.
- Published
- 2019
- Full Text
- View/download PDF
26. Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients.
- Author
-
Martini S, Arcadipane F, Strignano P, Spadi R, Contu V, Fiandra C, Ragona R, Catalano G, Satolli MA, Camandona M, Romagnoli R, Ricardi U, and Franco P
- Subjects
- Adult, Aged, Aged, 80 and over, Esophageal Neoplasms pathology, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Radiotherapy Dosage, Retrospective Studies, Survival Rate, Esophageal Neoplasms radiotherapy, Radiometry methods, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy, Intensity-Modulated methods
- Abstract
The aim of the study is to evaluate feasibility, safety, toxicity profile, and dosimetric results of volumetric modulated arc therapy (VMAT) to deliver definitive or pre-operative radiation in locally advanced esophageal cancer patients. A total of 68 patients were treated with VMAT between March 2014 and March 2018 (44% vs 56% for definitive and neoadjuvant settings, respectively). Dose prescription differed depending on the clinical scenario (54-60 Gy in 30 fractions for definitive treatments; 41.4/45 Gy in 23-25 fractions in the pre-operative setting). Most of the patients were given concurrent chemotherapy. Two coplanar and one non-coplanar arcs were employed for VMAT delivery. Treatment was generally well tolerated. Acute toxicity was generally mild. In patients treated with definitive intent, ≥ G3 toxicities were observed for esophagitis (30%), anorexia (26.7%), fatigue (26.7%), nausea (6.7%), and vomiting (3.3%). In patients treated within a neoadjuvant approach, ≥ G3 anorexia (21%), esophagitis (15.8%), fatigue (13.3%), nausea (5.3%), and vomiting (2.6%) were observed. Dosimetric results were consistent in term of both target coverage and normal tissue sparing. In conclusion, VMAT proved to be a feasible, safe, and effective strategy to deliver definitive or pre-operative radiation in locally advanced esophageal cancer patients.
- Published
- 2018
- Full Text
- View/download PDF
27. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
- Author
-
Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, and Leone F
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bile Duct Neoplasms drug therapy, Bile Duct Neoplasms genetics, Bile Duct Neoplasms metabolism, Biliary Tract Neoplasms metabolism, Cholangiocarcinoma drug therapy, Cholangiocarcinoma genetics, Cholangiocarcinoma metabolism, DNA Mutational Analysis, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, ErbB Receptors antagonists & inhibitors, ErbB Receptors metabolism, Gallbladder Neoplasms drug therapy, Gallbladder Neoplasms genetics, Gallbladder Neoplasms metabolism, Gene Amplification, Humans, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds therapeutic use, Oxaliplatin, Panitumumab, Prognosis, Gemcitabine, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms genetics, ErbB Receptors genetics, Genes, erbB-1, Mutation
- Abstract
The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. Multiple mechanisms might be involved in the resistance to anti-EGFR. Here, we explored the mutation profile of EGFR extracellular domain (ECD), of tyrosine kinase domain (TKD), and its amplification status. EGFR mutational status of exons 12, 18-21 was analyzed in 57 tumors by Sanger sequencing. EGFR amplification was evaluated in 37 tumors by Fluorescent In Situ Hybridization (FISH). Kaplan-Meier curves were calculated using the log-rank test. Six patients had mutations in exon 12 of EGFR ECD and 7 in EGFR TKD. Neither EGFR ECD nor TKD mutations affected progression free survival (PFS) or overall survival (OS) in the entire population. In the panitumumab plus GEMOX (P-GEMOX) arm, ECD mutated patients had a worse OS, while EGFR TKD mutated patients had a trend towards shorter PFS and OS. Overall, the presence of mutations in EGFR or in its transducers did not affect PFS or OS, while the extrahepatic cholangiocarcinoma (ECC) mutated patients had a worse prognosis compared to WT. Nineteen out of 37 tumors were EGFR amplified, but the amplification did not correlate with survival. ECC EGFR amplified patients had improved OS, whereas the amplification significantly correlated with poor PFS (p = 0.03) in gallbladder carcinoma patients. The high molecular heterogeneity is a predominant feature of BTC: the alterations found in this work seem to have a prognostic impact rather than a predictive role towards anti-EGFR therapy.
- Published
- 2018
- Full Text
- View/download PDF
28. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials.
- Author
-
Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, and Ricardi U
- Subjects
- Clinical Trials, Phase III as Topic, Combined Modality Therapy, Humans, Randomized Controlled Trials as Topic, Adenocarcinoma therapy, Esophageal Neoplasms therapy, Esophagogastric Junction, Stomach Neoplasms therapy
- Abstract
Adenocarcinomas of the lower oesophagus and gastro-oesophageal junction are a complex clinico-pathological setting. Multimodality therapy is considered mandatory in most disease presentations. Nevertheless, the most appropriate treatment package has yet to be established. We herein summarize the evidence derived from randomized phase III trials on pre-operative treatments in this oncological scenario.
- Published
- 2017
- Full Text
- View/download PDF
29. Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.
- Author
-
Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, and Tonini G
- Published
- 2016
- Full Text
- View/download PDF
30. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.
- Author
-
Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, and Satolli MA
- Abstract
Pancreatic cancer (PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease.
- Published
- 2016
- Full Text
- View/download PDF
31. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.
- Author
-
Niccolai E, Taddei A, Ricci F, Rolla S, D'Elios MM, Benagiano M, Bechi P, Bencini L, Ringressi MN, Pini A, Castiglione F, Giordano D, Satolli MA, Coratti A, Cianchi F, Bani D, Prisco D, Novelli F, and Amedei A
- Subjects
- Adult, Aged, Aged, 80 and over, Apoptosis, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal mortality, Carcinoma, Pancreatic Ductal pathology, Cell Line, Tumor, Coculture Techniques, Cytotoxicity, Immunologic, Female, Granzymes metabolism, Humans, Interferon-gamma immunology, Interleukins immunology, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms immunology, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology, Perforin metabolism, Phenotype, Signal Transduction, T-Lymphocytes, Helper-Inducer immunology, T-Lymphocytes, Helper-Inducer pathology, Interleukin-22, Carcinoma, Pancreatic Ductal metabolism, Interferon-gamma metabolism, Interleukins metabolism, Lymphocytes, Tumor-Infiltrating metabolism, Pancreatic Neoplasms metabolism, Paracrine Communication, T-Lymphocytes, Helper-Inducer metabolism
- Abstract
PDAC (pancreatic ductal adenocarcinoma) is the fifth leading cause of cancer-related death. The causes of this cancer remain unknown, but increasing evidence indicates a key role of the host immune response and cytokines in human carcinogenesis. Intra-tumoral IL (interleukin)-22 levels have been shown to be elevated in PDAC patients. However, little is known regarding the expression and clinical relevance of Th22 cells in human PDAC and, furthermore, which TILs (tumour-infiltrating lymphocytes) are the main producers of IL-22 is unknown. In the present study, we characterized the functional proprieties of the different subsets of IL-22-producing TILs and analysed their relationship with the TNM staging system and patient survival. We have demonstrated for the first time that, in PDAC patients, the T-cells co-producing IFN-γ (interferon γ) and exerting perforin-mediated cytotoxicity are the major intra-tumoral source of IL-22. In addition, isolated Th22 cells were able to induce apoptosis, which was antagonized by IL-22. Finally, we observed that the IL-22-producing T-cells were significantly increased in tumour tissue and that this increase was positively correlated with TNM staging of PDAC and poorer patient survival. These novel findings support the dual role of the anti-tumour immune system and that IL-22-producing cells may participate in PDAC pathogenesis. Therefore monitoring Th22 levels could be a good diagnostic parameter, and blocking IL-22 signalling may represent a viable method for anti-PDAC therapies., (© 2016 Authors; published by Portland Press Limited.)
- Published
- 2016
- Full Text
- View/download PDF
32. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.
- Author
-
Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, and Tonini G
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Young Adult, Bone Neoplasms secondary, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Lung Neoplasms pathology
- Abstract
We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.
- Published
- 2015
- Full Text
- View/download PDF
33. Gastric cancer: The times they are a-changin'.
- Author
-
Satolli MA, Buffoni L, Spadi R, and Roato I
- Abstract
Gastric cancer is the third leading cause of cancer death worldwide. Even though during these last decades gastric cancer incidence decreased in Western countries, it remains endemic and with a high incidence in Eastern countries. The survival in advanced and metastatic stage of gastric cancer is still very poor. Recently the Cancer Genoma Atlas Research Network identified four subtypes with different molecular profiles to classify gastric cancer in order to offer the optimal targeted therapies for pre-selected patients. Indeed, the key point is still the selection of patients for the right treatment, on basis of molecular tumor characterization. Since chemotherapy reached a plateau of efficacy for gastric cancer, the combination between cytotoxic therapy and biological agents gets a better prognosis and decreases chemotherapeutic toxicity. Currently, Trastuzumab in combination with platinum and fluorouracil is the only approved targeted therapy in the first line for c-erbB2 positive patients, whereas Ramucirumab is the only approved targeted agent for patients with metastatic gastric cancer. New perspectives for an effective treatment derived from the immunotherapeutic strategies. Here, we report an overview on gastric cancer treatments, with particular attention to recent advances in targeted therapies and in immunotherapeutic approach.
- Published
- 2015
- Full Text
- View/download PDF
34. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
- Author
-
Brossa A, Grange C, Mancuso L, Annaratone L, Satolli MA, Mazzone M, Camussi G, and Bussolati B
- Subjects
- Animals, Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Cell Hypoxia, Cell Proliferation drug effects, Cell Survival drug effects, Cells, Cultured, Endothelial Progenitor Cells enzymology, Endothelial Progenitor Cells pathology, Humans, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Mice, SCID, Neoplastic Stem Cells enzymology, Neoplastic Stem Cells pathology, Neovascularization, Pathologic, Neovascularization, Physiologic drug effects, RNA Interference, Signal Transduction drug effects, Sunitinib, Time Factors, Transfection, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor Receptor-2 genetics, Vascular Endothelial Growth Factor Receptor-2 metabolism, Angiogenesis Inhibitors pharmacology, Bevacizumab pharmacology, Cell Differentiation drug effects, Endothelial Progenitor Cells drug effects, Indoles pharmacology, Neoplastic Stem Cells drug effects, Protein Kinase Inhibitors pharmacology, Pyrroles pharmacology, Vascular Endothelial Growth Factor A antagonists & inhibitors, Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors
- Abstract
Different mechanisms of angiogenesis and vasculogenesis are involved in the development of the tumor vasculature. Among them, cancer stem cells are known to contribute to tumor vasculogenesis through their direct endothelial differentiation. Here, we investigated the effect of anti-angiogenic therapy on vasculogenesis of cancer stem cells derived from breast and renal carcinomas. We found that all the anti-angiogenic approaches impaired proliferation and survival of cancer stem cells once differentiated into endothelial cells in vitro and reduced murine angiogenesis in vivo. At variance, only VEGF-receptor inhibition using the non-specific tyrosine kinase inhibitor Sunitinib or the anti-VEGF-receptor 2 neutralizing antibody, but not VEGF blockade using Bevacizumab, impaired the process of endothelial differentiation in vitro, suggesting a VEGF-independent mechanism. In addition, tyrosine kinase inhibition by Sunitinib but not VEGF blockade using the soluble VEGF trap sFlk1 inhibited the cancer stem cell-induced vasculogenesis in vivo. Accordingly, Sunitinib but not Bevacizumab inhibited the induction of hypoxia-inducible factor pathway occurring during endothelial differentiation under hypoxia. The present results highlight a differential effect of VEGF-receptor blockade versus VEGF inhibition in tumor vascularization. VEGFR blockade inhibits the process of tumor vasculogenesis occurring during tumor hypoxia whereas the effect of VEGF inhibition appears restricted to differentiated endothelial cells.
- Published
- 2015
- Full Text
- View/download PDF
35. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
- Author
-
Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, and Santini D
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Analysis, Bone Neoplasms mortality, Bone Neoplasms secondary, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell pathology, Kidney Neoplasms mortality, Kidney Neoplasms pathology
- Abstract
Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC)., Materials and Methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: <1 year, between 1 and 5 years and >5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance., Results: 470 patients were enrolled in this analysis. In 19 patients (4%),bone was the only metastatic site; 277 patients had concomitant metastases in other sites. Median time to BMs was 16 months (range 0 - 44y) with Median OS of 17 months. Number of metastatic sites (including bone, p = 0.01), concomitant metastases, high Fuhrman grade (p < 0.001) and non-clear cell histology (p = 0.013) were significantly associated with poor prognosis. Patients with TTBM >5 years had longer OS (22 months) compared to patients with TTBM <1 year (13 months) or between 1 and 5 years (19 months) from nephrectomy (p < 0.001), no difference was found between these two last groups (p = 0.18). At multivariate analysis, ECOG-PS, MSKCC group and concomitant lung or lymph node metastases were independent predictors of OS in patients with BMs., Conclusions: Our study suggest that age, ECOG-PS, histology, MSKCC score, TTBM and the presence of concomitant metastases should be considered in order to optimize the management of RCC patients with BMs.
- Published
- 2015
- Full Text
- View/download PDF
36. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients.
- Author
-
Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C, Amici A, Cavallo F, Cappello P, Pierobon D, Novelli F, and Giovarelli M
- Subjects
- Animals, Cancer Vaccines pharmacology, Dendritic Cells immunology, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Humans, Immune Tolerance immunology, Immunohistochemistry, Mice, Mice, Inbred NOD, Mice, SCID, Plasmids, Rats, Recombinant Fusion Proteins immunology, Recombinant Fusion Proteins pharmacology, Transfection, Transplantation Chimera, Vaccines, DNA pharmacology, Xenograft Model Antitumor Assays, Breast Neoplasms immunology, Cancer Vaccines immunology, Pancreatic Neoplasms immunology, Receptor, ErbB-2 immunology, Vaccines, DNA immunology
- Abstract
Purpose: Despite the great success of HER2 vaccine strategies in animal models, effective clinical results have not yet been obtained. We studied the feasibility of using DNA coding for chimeric rat/human HER2 as a tool to break the unresponsiveness of T cells from patients with HER2-overexpressing tumors (HER2-CP)., Experimental Design: Dendritic cells (DCs) generated from patients with HER2-overexpressing breast (n = 28) and pancreatic (n = 16) cancer were transfected with DNA plasmids that express human HER2 or heterologous rat sequences in separate plasmids or as chimeric constructs encoding rat/human HER2 fusion proteins and used to activate autologous T cells. Activation was evaluated by IFN-γ ELISPOT assay, perforin expression, and ability to halt HER2+ tumor growth in vivo., Results: Specific sustained proliferation and IFN-γ production by CD4 and CD8 T cells from HER2-CP was observed after stimulation with autologous DCs transfected with chimeric rat/human HER2 plasmids. Instead, T cells from healthy donors (n = 22) could be easily stimulated with autologous DCs transfected with any human, rat, or chimeric rat/human HER2 plasmid. Chimeric HER2-transfected DCs from HER2-CP were also able to induce a sustained T-cell response that significantly hindered the in vivo growth of HER2(+) tumors. The efficacy of chimeric plasmids in overcoming tumor-induced T-cell dysfunction relies on their ability to circumvent suppressor effects exerted by regulatory T cells (Treg) and/or interleukin (IL)-10 and TGF-β1., Conclusions: These results provide the proof of concept that chimeric rat/human HER2 plasmids can be used as effective vaccines for any HER2-CP with the advantage of being not limited to specific MHC. Clin Cancer Res; 20(11); 2910-21. ©2014 AACR., (©2014 American Association for Cancer Research.)
- Published
- 2014
- Full Text
- View/download PDF
37. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
- Author
-
Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzì V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, and Bracarda S
- Subjects
- Bone Neoplasms epidemiology, Diphosphonates therapeutic use, Disease Progression, Female, Humans, Italy epidemiology, Kidney Neoplasms epidemiology, Male, Retrospective Studies, Bone Neoplasms secondary, Kidney Neoplasms pathology
- Abstract
Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC., Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed., Results: Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05)., Conclusions: RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.
- Published
- 2013
- Full Text
- View/download PDF
38. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.
- Author
-
Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, and Santini D
- Subjects
- Adult, Aged, Bone Density Conservation Agents therapeutic use, Bone Neoplasms drug therapy, Bone Neoplasms mortality, Diphosphonates therapeutic use, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Patient Outcome Assessment, Population Surveillance, Prognosis, Retrospective Studies, Bone Neoplasms epidemiology, Bone Neoplasms secondary, Stomach Neoplasms pathology
- Abstract
Background: Bone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available., Patients and Methods: Data on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed., Results: Median time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and three events, respectively. Median times to first and second SRE were 2 and 4 months, respectively. Median survival was 6 months after bone metastasis diagnosis and 3 months after first SRE. Median survival in patients who did not experience SREs was 5 months. Among patients who received zoledronic acid before the first SRE, the median time to appearance of first SRE was significantly prolonged compared to control (7 months vs 4 months for control; P: 0.0005)., Conclusions: To our knowledge, this retrospective analysis is the largest multicenter study to demonstrate that bone metastases from GC are not so rare, are commonly aggressive and result in relatively early onset of SREs in the majority of patients. Indeed, our large study, which included 90 patients treated with ZOL, showed, for the first time in literature, a significant extension of time to first SRE and increase in the median survival time after diagnosis of bone metastasis. Taken together, these data may support the beneficial effects of ZOL in GC patients.
- Published
- 2013
- Full Text
- View/download PDF
39. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
- Author
-
Novarino AM, Satolli MA, Chiappino I, Giacobino A, Napoletano R, Ceccarelli M, Ciccone G, Schena M, Bertetto O, and Ciuffreda L
- Subjects
- Adolescent, Adult, Aged, Biliary Tract Neoplasms mortality, Biliary Tract Neoplasms pathology, Bone Neoplasms drug therapy, Bone Neoplasms mortality, Bone Neoplasms secondary, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Fluorouracil administration & dosage, Follow-Up Studies, Humans, Leucovorin administration & dosage, Liver Neoplasms drug therapy, Liver Neoplasms mortality, Liver Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Lung Neoplasms secondary, Male, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Organoplatinum Compounds administration & dosage, Oxaliplatin, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms mortality, Peritoneal Neoplasms secondary, Prognosis, Retrospective Studies, Survival Rate, Young Adult, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biliary Tract Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Objectives: We conducted a retrospective cohort study to compare 2 different chemotherapy regimens for advanced biliary tract cancer (BTC)., Methods: Records of patients consecutively treated in our institution for advanced BTC from 2001 to 2006 were retrieved. Chemotherapy treatment with FOLFOX-4 regimen was routinely offered as first option; gemcitabine (GEM) as single agent was proposed as an alternative option to patients who refused central venous catheter implantation. Toxicity, overall response rate, progression-free survival (PFS), and overall survival (OS) obtained with the 2 treatments were evaluated., Results: Twenty-two patients were treated with FOLFOX-4, whereas 18 patients received GEM. In the FOLFOX-4 group, the overall response rate was 13.6% (95% confidence interval [CI], 4.7-33.3), with 1 complete response and 2 partial responses, and 54.5% (95% CI, 34.7-73.1) of disease control rate (complete response+partial response+stable disease). Median OS was 14.1 months (95% CI, 9.1-18.8) and median PFS 5.44 months (95% CI, 3.2-6.3). In the GEM group, we observed no objective response, whereas 27.7% (95% CI, 12.5-50.9) obtained disease control. Median OS was 8.3 months (95% CI, 4.7-12.9) and median PFS 3.9 months (95% CI, 2.2-5.4). Toxicity, mainly hematological, was acceptable for both treatments. On a multivariable Cox model including a propensity score, only the performance status and chemotherapy regimen were confirmed as strong predictors of OS, with an hazard ratio of 0.49 (95% CI, 0.24-0.99) in favor of FOLFOX-4., Conclusions: The combination chemotherapy with oxaliplatin and 5-fluorouracil is well tolerated and seems to provide prolonged survival than GEM alone in advanced BTC treatment, but further randomized trials are warranted.
- Published
- 2013
- Full Text
- View/download PDF
40. Bone metastases in gastric cancer follow a RANKL-independent mechanism.
- Author
-
D'Amico L, Satolli MA, Mecca C, Castiglione A, Ceccarelli M, D'Amelio P, Garino M, De Giuli M, Sandrucci S, Ferracini R, and Roato I
- Subjects
- Aged, Bone Neoplasms pathology, Female, Gene Expression Regulation, Neoplastic, Humans, Intercellular Signaling Peptides and Proteins blood, Interleukin-7 blood, Leukocytes, Mononuclear cytology, Lymphotoxin-alpha blood, Male, Middle Aged, Neoplasm Staging, Neovascularization, Pathologic blood, Osteoclasts cytology, Osteoclasts metabolism, Osteoprotegerin blood, Stomach Neoplasms genetics, Stomach Neoplasms pathology, Tumor Necrosis Factor-alpha blood, Vascular Endothelial Growth Factor A blood, Bone Neoplasms blood, Bone Neoplasms secondary, RANK Ligand blood, Stomach Neoplasms blood
- Abstract
Gastric cancer is one of the most common and lethal malignancies worldwide. Bone metastases in gastric cancer are less common than in other solid tumors, but when they occur the prognosis is generally poor. Increased osteoclastogenesis and osteoclast activity are common features in bone metastases caused by different osteotropic cancer. We investigated osteoclastogenesis and its mechanisms in gastric cancer by enrolling 31 newly diagnosed gastric cancer patients and 45 healthy controls. We studied in vitro osteoclastogenesis in the peripheral blood mononuclear cell cultures of patients and controls, showing spontaneous osteoclastogenesis for half of the patients. This osteoclastogenesis was RANKL- and TNF-α-independent. We analyzed primary tumor and bone metastatic tissues of gastric cancer for the expression of genes involved in osteoclastogenesis. The expression of transforming growth factor-β (TGF-β), osteoprotegerin (OPG), IL-7 and dickkopf-1 (DKK-1) was higher in primary tumors than in bone metastases. RANKL was not detectable in primary tumor or in bone metastatic tissue. The serum RANKL level was significantly higher in healthy controls than in patients, and it was not related to osteoclastogenesis, thereby suggesting that RANKL is not involved in the bone metastatic mechanisms in gastric cancer. We hypothesized a role of RANKL in angiogenesis, thus we compared the serum levels of RANKL to those of VEGF, since VEGF is directly related to angiogenesis. Different from RANKL, the VEGF serum levels were higher in gastric patients than in controls, suggesting a block of the angiogenesis inhibition due to RANKL. RANKL and VEGF serum levels were not predictive of overall survival in our cohort of gastric patients.
- Published
- 2013
- Full Text
- View/download PDF
41. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer.
- Author
-
Asioli S, Maletta F, Verdun di Cantogno L, Satolli MA, Schena M, Pecchioni C, Botta C, Chiusa L, Molinaro L, Conti L, Viale G, Ingravallo G, Maiorano E, and Sapino A
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma surgery, Adult, Aged, Aged, 80 and over, Female, Humans, Immunohistochemistry, Lymph Nodes pathology, Lymphatic Metastasis, Male, Middle Aged, Prognosis, Reproducibility of Results, Specimen Handling methods, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Survival Rate, Tissue Array Analysis, Adenocarcinoma metabolism, Biomarkers, Tumor metabolism, Receptor, ErbB-2 metabolism, Stomach Neoplasms metabolism
- Abstract
Gastric cancer shows intratumoral heterogeneity for human epidermal growth factor receptor 2 expression. We evaluated whether the number of tissue blocks analyzed or the antibodies used may influence the immunohistochemical results in gastrectomy specimens. Clinicopathologic data from 148 patients receiving gastric surgery for cancer were collected. One tissue block for each of 88 primary tumors and 60 paired primary tumors and metastases was examined for human epidermal growth factor receptor 2 status by immunohistochemistry using 3 different antibodies (HercepTest, CB11, and 4B5) and by fluorescent in situ hybridization. Two additional tissue blocks of the primary tumor were tested by immunohistochemistry if the results were negative on the first tissue block. The concordance among the 3 antibodies was 94.5% (testing 1 tissue block). Two cases showed a clinically significant discrepancy between primary tumor (score 0) and lymph nodes metastases (score 3+). Additional block analysis increased both the sensitivity (from 63% to 83%) and the accuracy (from 91% to 94%) of immunohistochemistry as compared with fluorescent in situ hybridization. The multiblock approach could potentially identify a greater number of human epidermal growth factor receptor 2-positive gastric cancers, particularly those with higher levels of intratumor heterogeneity. In turn, human epidermal growth factor receptor 2 positivity correlated with a worse prognosis (P=.011) and was an independent variable in multivariate analysis (hazard ratio, 1.57). In conclusion, testing more than 1 tissue block of cancer from specimens of gastric resection provides a more reliable human epidermal growth factor receptor 2 assessment regardless of the antibody used., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
42. Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma.
- Author
-
Vizio B, Mauri FA, Prati A, Trivedi P, Giacobino A, Novarino A, Satolli MA, Ciuffreda L, Camandona M, Gasparri G, and Bellone G
- Subjects
- Adult, Aged, Carcinoma, Pancreatic Ductal pathology, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Neoplastic Stem Cells pathology, Pancreas metabolism, Pancreatic Neoplasms pathology, Biomarkers, Tumor analysis, Carcinoma, Pancreatic Ductal metabolism, Neoplastic Stem Cells metabolism, Pancreatic Neoplasms metabolism
- Abstract
Chemoresistance and self-renewal of cancer stem cells (CSC), found in many tumors including pancreatic ductal adenocarcinoma (PDAC), are believed to underlie tumor mass regrowth. The distribution of cells carrying the putative stem-cell markers CD133, Nestin, Notch1-4, Jagged1 and 2, ABCG2 and aldehyde dehydrogenase (ALDH1) was assessed immunohistochemically using PDAC and normal pancreas tissue microarrays. The immunoreactivity was semi-quantitatively graded against the normal pancreas and was correlated with the differentiation grade and disease stage. No statistical significant differences were found between normal pancreas and PDAC in the expression of Nestin, Notch1, 3 and 4, ABCG2 or ALDH1. Notch2 and Jagged1 and 2 expression were increased in PDAC. CD133-positive cells were above-normal in PDAC, but the difference was not statistically significant. Nestin, Notch1-4, Jagged1, ABCG2 and ALDH1 immunostaining scores were not correlated with tumor grade or disease stage. CD133 and Notch2 expression was significantly inversely correlated with tumor grade, but not disease stage. Notch3 immunostaining positively correlated with tumor stage, but not with differentiation grade. Jagged2 protein expression correlated inversely with disease stage, but not with tumor grade. From the clinical standpoint, improved delineation of the tumor CSC signature, putatively responsible for tumor initiation and recurrence after initial response to chemotherapy, may offer novel therapeutic targets for this highly lethal cancer.
- Published
- 2012
- Full Text
- View/download PDF
43. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
- Author
-
Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, and Tonini G
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Breast Neoplasms pathology, Breast Neoplasms, Male drug therapy, Breast Neoplasms, Male mortality, Cohort Studies, Drug Resistance, Neoplasm drug effects, Female, Humans, Male, Middle Aged, Retrospective Studies, Trastuzumab, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Smoking adverse effects
- Abstract
Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and <10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients.
- Published
- 2011
- Full Text
- View/download PDF
44. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
- Author
-
Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, Milanesi E, Bertetto O, and Ciuffreda L
- Subjects
- Adenocarcinoma secondary, Adult, Aged, Cohort Studies, Female, Fluorouracil administration & dosage, Humans, Infusions, Intravenous, Leucovorin administration & dosage, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Lymphatic Metastasis, Male, Maximum Tolerated Dose, Middle Aged, Organoplatinum Compounds administration & dosage, Oxaliplatin, Pancreatic Neoplasms pathology, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms secondary, Prognosis, Survival Rate, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Pancreatic Neoplasms drug therapy, Salvage Therapy
- Abstract
Objective: A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule., Methods: Patients received weekly intravenous infusions of oxaliplatin 40 mg/m, 5-FU 500 mg/m, and leucovorin 250 mg/m (3 weeks on, 1 week off)., Results: Twenty-three patients affected with metastatic (16) or locally advanced (7) pancreas adenocarcinoma were involved in this study. A total of 148 weeks of chemotherapy was delivered (median 2 courses each patient). Among 17 assessable patients, no objective response was registered and 4 patients had stable disease, whereas 13 had tumor progression. Median duration of stable disease was 14 weeks. Median time to progression of disease (TTP) was 11.6 weeks [95% confidence interval (CI), 7.6-5.6]. Kaplan-Meier estimated median overall survival (OS) was 17.1 week (95% CI, 4.0-30.1) and 3 months survival rate was 69.6%. Seven patients experienced grade 3 to 4 toxicity. The regimen was associated with 36% clinical benefit., Conclusions: The median TTP and median OS in this population with poor prognosis suggests some activity, however, only further investigations will be able to establish the clinical value of this combination.
- Published
- 2009
- Full Text
- View/download PDF
45. [The role of angiogenesis in renal carcinoma].
- Author
-
Bussolati B, Satolli MA, and Camussi G
- Subjects
- Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Benzenesulfonates therapeutic use, Bevacizumab, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Drug Therapy, Combination, Endothelial Growth Factors biosynthesis, Endothelial Growth Factors genetics, Endothelium, Vascular metabolism, Endothelium, Vascular pathology, Humans, Indoles therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics, Neovascularization, Pathologic drug therapy, Neovascularization, Pathologic genetics, Niacinamide analogs & derivatives, PAX2 Transcription Factor metabolism, Phenotype, Phenylurea Compounds, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins c-akt metabolism, Pyridines therapeutic use, Pyrroles therapeutic use, Sorafenib, Sunitinib, Thrombospondin 1 metabolism, Vascular Endothelial Growth Factor Receptor-1 metabolism, Carcinoma, Renal Cell blood supply, Carcinoma, Renal Cell metabolism, Endothelial Growth Factors metabolism, Kidney Neoplasms blood supply, Kidney Neoplasms metabolism, Neovascularization, Pathologic metabolism
- Abstract
Renal cell carcinoma is characterized by intense angiogenesis associated with the inactivation of the von Hippel-Lindau oncosuppressor gene with consequent hyperexpression of proangiogenic factors. Functional and molecular characterization of renal tumor endothelial cells has demonstrated an increase in angiogenesis and cell survival. The proangiogenic phenotype was due to hyperactivation of the PI3K/Akt/mTor pathway, which downregulates the synthesis of the antiangiogenic factor thrombospondin-1. Moreover, renal tumor endothelial cells presented an immature and embryonic phenotype with expression of the embryonic kidney-specific gene PAX-2. It is conceivable that the endothelium present in renal carcinoma is heterogeneous, with a possible origin from adjacent vessels, resident or circulating stem cells, or from the tumor cells themselves. The relevance of the angiogenic process in renal carcinoma is underlined by the therapeutic effect of antiangiogenic drugs. Different drugs against VEGF, such as the anti-VEGF monoclonal antibody bevacizumab, and small molecule tyrosine-kinase inhibitors, such as sunitinib and sorafenib, showed a clinical effect in patients with metastatic carcinoma. However, antiangiogenic therapy, although beneficial, is not sufficient per se. These studies suggest a role for the angiogenic program in the growth and dissemination of renal carcinoma and indicate the need for new therapeutic strategies.
- Published
- 2008
46. Lymphoscintigraphic localization of sentinel node in early colorectal cancer: results of a monocentric study.
- Author
-
Sandrucci S, Mussa B, Goss M, Mistrangelo M, Satolli MA, Sapino A, Bellò M, Bisi G, and Mussa A
- Subjects
- Feasibility Studies, Humans, Radionuclide Imaging, Technetium Tc 99m Aggregated Albumin, Colorectal Neoplasms pathology, Lymph Nodes diagnostic imaging, Lymphatic Metastasis diagnostic imaging, Rosaniline Dyes
- Abstract
Background and Objectives: Evaluation of the feasibility of the sentinel node technique in early colorectal neoplasms and its overall accuracy in predicting nodal metastases., Methods: Thirty-five patients with colon or rectal lesions or degenerate polyps not radically excised by endoscopy were included. Lymphatic mapping was performed with 99mTc labeled albumin colloid injected submucosally by an endoscopic route the afternoon before the surgical procedure. The day of the intervention, 2.5% patent blue V dye (S.A.L.F: Italy) was injected circumferentially around the tumor. A hand held gamma detecting probe (Scintiprobe m100, Pol-Hi-Tech, Italy) was employed to detect "hot" nodes, in vivo and ex vivo. All sentinel nodes were embedded separately for haematoxylin and eosin staining. No IHC or PCR techniques were employed., Results: Sentinel lymph nodes (SLN) were successfully identified in 35 out of 35 patients. Concordance between SLN and nodal status was observed in 32 out of 35 cases (91.4%); four patients (11.4%) were upstaged. Three skip nodal metastases were observed (false-negative rate: 8.5%)., Conclusions: The sentinel node technique with blue dye and radiotracer seems valuable in early colorectal cancers detected by screening programs: a good organization and a learning curve are needed, as further multicentric studies.
- Published
- 2007
- Full Text
- View/download PDF
47. "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
- Author
-
Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, and Cassoni P
- Subjects
- Aged, Biomarkers, Tumor analysis, Brain Neoplasms diagnostic imaging, Brain Neoplasms surgery, Female, Humans, Lung Neoplasms diagnostic imaging, Lung Neoplasms surgery, Meningioma diagnostic imaging, Meningioma surgery, Neoplasm Metastasis pathology, Tomography, X-Ray Computed, Brain Neoplasms pathology, Lung Neoplasms secondary, Meningioma secondary
- Abstract
Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest. We, here, report of a 70-year-old healthy woman found by CT scan to have multiple lesions, the two largest in the right lung on routine examination. Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before. The larger lung lesion was a 3-cm node located in the right lung and was removed by wedge resection. Macroscopically, it showed well-defined borders, whitish colour and firm consistency; histologically, it was uniformly composed by spindle meningothelial cells arranged in fascicules including psammoma bodies. The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung. Lung metastatic meningiomas may be a diagnostic challenge because of their unusual site of presentation and the possible confusion with primitive lung meningiomas or primary mesenchymal lung lesions. They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
- Published
- 2007
- Full Text
- View/download PDF
48. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma.
- Author
-
Matera L, Galetto A, Bello M, Baiocco C, Chiappino I, Castellano G, Stacchini A, Satolli MA, Mele M, Sandrucci S, Mussa A, Bisi G, and Whiteside TL
- Abstract
Background: Besides being the effectors of native anti-tumor cytotoxicity, NK cells participate in T-lymphocyte responses by promoting the maturation of dendritic cells (DC). Adherent NK (A-NK) cells constitute a subset of IL-2-stimulated NK cells which show increased expression of integrins and the ability to adhere to solid surface and to migrate, infiltrate, and destroy cancer. A critical issue in therapy of metastatic disease is the optimization of NK cell migration to tumor tissues and their persistence therein. This study compares localization to liver metastases of autologous A-NK cells administered via the systemic (intravenous, i.v.) versus locoregional (intraarterial, i.a.) routes., Patients and Methods: A-NK cells expanded ex-vivo with IL-2 and labeled with (111)In-oxine were injected i.a. in the liver of three colon carcinoma patients. After 30 days, each patient had a new preparation of (111)In-A-NK cells injected i.v. Migration of these cells to various organs was evaluated by SPET and their differential localization to normal and neoplastic liver was demonstrated after i.v. injection of 99mTc-phytate., Results: A-NK cells expressed a donor-dependent CD56+ CD16+ CD3- (NK) or CD56+ CD16+ CD3+ (NKT) phenotype. When injected i.v., these cells localized to the lung before being visible in the spleen and liver. By contrast, localization of i.a. injected A-NK cells was virtually confined to the spleen and liver. Binding of A-NK cells to liver neoplastic tissues was observed only after i.a. injections., Conclusion: This unique study design demonstrates that A-NK cells adoptively transferred to the liver via the intraarterial route have preferential access and substantial accumulation to the tumor site.
- Published
- 2006
- Full Text
- View/download PDF
49. Sentinel lymph node mapping in colorectal cancer: a feasibility study.
- Author
-
Evangelista W, Satolli MA, Malossi A, Mussa B, and Sandrucci S
- Subjects
- Aged, Feasibility Studies, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging methods, Prognosis, Sentinel Lymph Node Biopsy methods, Colorectal Neoplasms pathology, Coloring Agents, Lymph Nodes pathology, Rosaniline Dyes
- Abstract
Aims and Background: Sentinel lymph node (SLN) biopsy is currently used and investigated in melanoma and in breast cancer. Its utility in gastrointestinal malignancies is still under debate. The prognosis of colorectal cancer patients is strongly related to the lymphatic involvement. The aim of this study was to evaluate the feasibility of SLN mapping in colorectal cancer and to assess its impact on pathological staging and treatment., Methods and Study Design: We injected blue dye in 11 colorectal cancer patients during surgery. After resection the tumor specimen was examined to identify blue-stained lymph nodes and these lymph nodes were sent separately to the pathologist. Routine hematoxylin-eosin examination was performed on all nodes (including blue ones). No other techniques (eg immunohistochemistry or PCR) were performed., Results: Sentinel lymph nodes were successfully identified in 10 of the 11 patients. We observed only one false negative result (10%) and the agreement between SLN and other lymph node status was 80% (8/10). One patient was upstaged: SLN was positive for metastases while the other lymph nodes were negative., Conclusions: Lymphatic mapping using patent blue dye is feasible in colorectal cancer. The identification of lymph nodal metastases by this technique led to upstaging of one patient, who may benefit from adjuvant therapy. These initial results prompt further investigation of this procedure as an accurate, minimally invasive staging approach in early colorectal cancer. We proceed with our study to evaluate the role of SLN mapping in colorectal cancer management.
- Published
- 2002
50. [New therapeutic options in the treatment of hepatocellular carcinoma].
- Author
-
Martinotti R, Evangelista W, Goss M, Angelini F, and Satolli MA
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular radiotherapy, Carcinoma, Hepatocellular surgery, Catheter Ablation, Chemoembolization, Therapeutic, Combined Modality Therapy, Ethanol administration & dosage, Female, Hepatectomy, Humans, Liver Neoplasms drug therapy, Liver Neoplasms mortality, Liver Neoplasms radiotherapy, Liver Neoplasms surgery, Liver Transplantation, Male, Radiotherapy Dosage, Randomized Controlled Trials as Topic, Risk Factors, Time Factors, Carcinoma, Hepatocellular therapy, Liver Neoplasms therapy
- Abstract
Hepatocellular carcinoma (HCC) is the fourth cause of death for cancer, the first in northern Africa and is the eighth tumor for incidence in the world. Risk factors are: liver cirrhosis, HBV, HCV and natural toxins (i.e. aflatoxin). A screening program is feasible and based on serum alpha-fetoprotein dosage and periodic liver ultrasonography. Instrumental diagnosis is based on ultrasonography associated with angiography or spiral TC associated with systemic portography. The best therapy of HCC is based on a multimodal approach: surgery when feasible, associated with or in alternative to intratumoral ethanol injection (PEI), transcatheter arterial chemoembolization (TACE), chemotherapy and radiotherapy. These different therapeutical approaches are related to the liver extent of the disease and liver functioning. Poor results obtained with chemotherapy led to research different therapeutical approaches as hormonal substances, immune modulators or genetic modulators. Most patients present with advanced disease, and their survival rate decreases with the increase of liver cirrhosis concomitant with HCC. Better results should be obtained with the use of different therapeutical approaches as angiogenetic inhibitors, today only for experimental use at present.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.